Trends in decompensated cirrhosis and hepatocellular carcinoma among people with a hepatitis B notification in New South Wales
暂无分享,去创建一个
M. Alavi | G. Dore | J. Amin | M. Danta | B. Hajarizadeh | M. Martinello | G. Matthews | H. Valerio | M. Law | Syed Hassan Bin Usman Shah | J. George
[1] B. Cowie,et al. Time for universal hepatitis B screening for Australian adults , 2021, The Medical journal of Australia.
[2] P. Austin,et al. Diagnosis of Chronic Hepatitis B Pericomplication: Risk factors and Trends Over Time , 2020, Hepatology.
[3] M. Alavi,et al. High hepatitis C treatment uptake among people with recent drug dependence in New South Wales, Australia. , 2020, Journal of hepatology.
[4] S. McPhail,et al. Changing prevalence of aetiological factors and comorbidities among Australians hospitalised for cirrhosis , 2020, Internal medicine journal.
[5] M. Hellard,et al. Enhancing the hepatitis B care cascade in Australia: A cost‐effectiveness model , 2019, Journal of viral hepatitis.
[6] B. Cowie,et al. Modeling Progress Toward Elimination of Hepatitis B in Australia , 2019, Hepatology.
[7] G. Ahlenstiel,et al. Interferon Lambda and Liver Fibrosis. , 2019, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.
[8] S. Pascual,et al. Surveillance and diagnosis of hepatocellular carcinoma: A systematic review , 2019, World journal of clinical cases.
[9] M. Alavi,et al. Declining hepatitis C virus-related liver disease burden in the direct-acting antiviral therapy era in New South Wales, Australia. , 2019, Journal of hepatology.
[10] P. Kamath,et al. Burden of liver diseases in the world. , 2019, Journal of hepatology.
[11] B. Cowie,et al. Aiming for the elimination of viral hepatitis in Australia, New Zealand, and the Pacific Islands and Territories: Where are we now and barriers to meeting World Health Organization targets by 2030 , 2018, Journal of gastroenterology and hepatology.
[12] B. Cowie,et al. Cultural and linguistic diversity of people living with chronic hepatitis B in 2011–2016: changing migration, shifting epidemiology , 2018, Australian and New Zealand journal of public health.
[13] J. Lazarus,et al. Burden of liver disease in Europe: Epidemiology and analysis of risk factors to identify prevention policies. , 2018, Journal of hepatology.
[14] B. Sander,et al. Identifying cirrhosis, decompensated cirrhosis and hepatocellular carcinoma in health administrative data: A validation study , 2018, PloS one.
[15] G. Dore,et al. Uptake of direct‐acting antiviral treatment for chronic hepatitis C in Australia , 2018, Journal of viral hepatitis.
[16] M. Alavi,et al. Mortality trends among people with hepatitis B and C: a population-based linkage study, 1993-2012 , 2018, BMC Infectious Diseases.
[17] M. Porwal,et al. Using a chronic hepatitis B Registry to support population-level liver cancer prevention in Sydney, Australia , 2017, Clinical epidemiology.
[18] M. Buti,et al. The risk of hepatocellular carcinoma decreases after the first 5 years of entecavir or tenofovir in Caucasians with chronic hepatitis B , 2017, Hepatology.
[19] M. Alavi,et al. Late hepatitis B and C diagnosis in relation to disease decompensation and hepatocellular carcinoma development. , 2017, Journal of hepatology.
[20] C. la Vecchia,et al. Global trends and predictions in hepatocellular carcinoma mortality. , 2017, Journal of hepatology.
[21] M. Alavi,et al. Trends in hepatocellular carcinoma among people with HBV or HCV notification in Australia (2000-2014). , 2016, Journal of hepatology.
[22] M. Alavi,et al. Time to decompensated cirrhosis and hepatocellular carcinoma after an HBV or HCV notification: A population-based study. , 2016, Journal of hepatology.
[23] Fares Alahdab,et al. Antiviral therapy for chronic hepatitis B viral infection in adults: A systematic review and meta‐analysis , 2016, Hepatology.
[24] S. Hutchinson,et al. Comparative effectiveness of antiviral treatment for hepatitis B: a systematic review and Bayesian network meta-analysis , 2015, European journal of gastroenterology & hepatology.
[25] R. Bataller,et al. Trends in the management and burden of alcoholic liver disease , 2015, Journal of hepatology.
[26] H. Chan,et al. Risk of hepatocellular carcinoma in chronic hepatitis B: assessment and modification with current antiviral therapy. , 2015, Journal of hepatology.
[27] V. Wong,et al. Interferon-λ rs12979860 genotype and liver fibrosis in viral and non-viral chronic liver disease , 2015, Nature Communications.
[28] F. Poordad. Presentation and complications associated with cirrhosis of the liver , 2015, Current medical research and opinion.
[29] Lungen Lu,et al. Clinical Advances in Fibrosis Progression of Chronic Hepatitis B and C , 2014, Journal of clinical and translational hepatology.
[30] G. Wong,et al. Prediction of fibrosis progression in chronic viral hepatitis , 2014, Clinical and molecular hepatology.
[31] Lequn Li,et al. Hepatic Resection Associated With Good Survival for Selected Patients With Intermediate and Advanced-Stage Hepatocellular Carcinoma , 2014, Annals of surgery.
[32] Amit G. Singal,et al. Early Detection, Curative Treatment, and Survival Rates for Hepatocellular Carcinoma Surveillance in Patients with Cirrhosis: A Meta-analysis , 2014, PLoS medicine.
[33] B. Cowie,et al. The burden of chronic hepatitis B virus infection in Australia, 2011 , 2013, Australian and New Zealand journal of public health.
[34] G. Zoli,et al. Alcohol use in adults. , 2013, The New England journal of medicine.
[35] K. Cheung,et al. Meta‐analysis: the association of hepatitis B virus genotypes and hepatocellular carcinoma , 2013, Alimentary pharmacology & therapeutics.
[36] G. Dore,et al. Survival after diagnosis of hepatocellular carcinoma and potential impact of treatment in a hepatitis B or C infected cohort , 2012, Hepatology research : the official journal of the Japan Society of Hepatology.
[37] Heather Walters,et al. Validation of key behaviourally based mental health diagnoses in administrative data: suicide attempt, alcohol abuse, illicit drug abuse and tobacco use , 2012, BMC Health Services Research.
[38] Sharon Whipkey. A year from diagnosis. , 2011, Nephrology news & issues.
[39] A. Lok,et al. Incidence of hepatocellular carcinoma in chronic hepatitis B patients receiving nucleos(t)ide therapy: a systematic review. , 2010, Journal of hepatology.
[40] THE WORLD HEALTH ORGANIZATION , 1954 .
[41] M. Dickie,et al. Global Health Sector Strategy on Viral Hepatitis : What does it mean for Canadians ? , 2018 .
[42] E. Cholongitas,et al. The impact of newer nucleos(t)ide analogues on patients with hepatitis B decompensated cirrhosis , 2015, Annals of gastroenterology.
[43] C. Mackenzie,et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. , 1987, Journal of chronic diseases.
[44] K. Fushimi,et al. American Journal of Epidemiology Practice of Epidemiology Updating and Validating the Charlson Comorbidity Index and Score for Risk Adjustment in Hospital Discharge Abstracts Using Data from 6 Countries , 2022 .